NCT05364333

Brief Summary

Postoperative Acute Kidney Injury (AKI) is a common complication after heart transplantation (HTX) affecting outcome of patients. Remote ischemic preconditioning (RIPC) is an intervention that showed positive effect on incidence of AKI in elective cardiac surgery. Effects of RIPC on AKI in HTX patients have not been investigated to date. Recently new biomarkers have been established, showing high sensitivity and specificity for AKI. Especially, Insulin-Like Growth Factor Binding Protein 7 (IGFBP7) together with Tissue Inhibitor of Metalloproteinases-2 (TIMP-2), known as nephrocheck®, are diagnostic biomarkers in this context. Hence, the investigators want to conduct a randomized controlled feasibility and proof of concept trial to determine the effects of RIPC on AKI after HTX, defined/detected using postoperative urinary \[TIMP-2\]\*\[IGFBP-7\] concentration.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 4, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 6, 2022

Completed
26 days until next milestone

Study Start

First participant enrolled

June 1, 2022

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2024

Completed
Last Updated

May 1, 2024

Status Verified

April 1, 2024

Enrollment Period

1.9 years

First QC Date

May 4, 2022

Last Update Submit

April 30, 2024

Conditions

Keywords

orthotopic heart transplantationHTX

Outcome Measures

Primary Outcomes (1)

  • postoperative TIMP2-IGFBP7 concentration

    change in postoperative TIMP2-IGFBP7 concentration measured in urine of patients

    first 48 hours after HTX (arrival ICU, 24 hours after HTX, 48 hours after HTX)

Secondary Outcomes (5)

  • Postoperative urinary biomarker concentration

    first 48 hours after HTX (arrival ICU, 24 hours after HTX, 48 hours after HTX)

  • AKI and renal replacement therapy

    first 72 hours

  • Major adverse kidney events (MAKE)

    during 30 days after HTX

  • Major adverse cardiovascular events (MACE)

    during 30 days after HTX

  • Days alive and out of hospital

    during 30 days after HTX

Study Arms (2)

Sham RIPC

SHAM COMPARATOR

Control patients will be submitted to 3 cycles of sham RIPC. Each cycle of Sham RIPC consists of a pseudo ischemia of the left upper limb caused by inflating a blood pressure cuff to 20mmHg for 5 minutes followed by 5 minutes of reperfusion time.

Procedure: Remote ischemic preconditioning

RIPC

EXPERIMENTAL

Patients in the intervention group will be submitted to 3 cycles of RIPC. For each cycle of RIPC, a blood pressure cuff will be inflated at 200mmHg for 5 minutes (or at least 50mmHg above the systolic arterial blood pressure) followed by 5 minutes of reperfusion time.

Procedure: Remote ischemic preconditioning

Interventions

For each cycle of RIPC, a blood pressure cuff will be inflated to the non-dominant arm at 200mmHg for 5 minutes (or at least 50mmHg above the systolic arterial blood pressure) followed by 5 minutes of reperfusion time

RIPCSham RIPC

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \- adult patients (\>18 years) undergoing HTX

You may not qualify if:

  • Acute myocardial infarction up to 7 days before surgery
  • age younger than 18 years
  • pre-existing AKI
  • previous kidney transplantation
  • chronic kidney disease with a glomerular filtration rate less than 30ml/min
  • pregnancy
  • peripheral vascular disease affecting the upper limbs
  • hepato-renal syndrome
  • drug therapy with sulfonamide or nicorandil

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Duesseldorf

Düsseldorf, North Rhine-Westphalia, 40225, Germany

Location

Study Officials

  • René M'Pembele, M.D.

    Heinrich-Heine University, Duesseldorf

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 4, 2022

First Posted

May 6, 2022

Study Start

June 1, 2022

Primary Completion

April 30, 2024

Study Completion

April 30, 2024

Last Updated

May 1, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share

Locations